Key result
Clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing myocardial infarction, stroke, or cardiovascular death.
Why the study?
Does clopidogrel plus aspirin reduce the rate of myocardial infarction, stroke, or death from cardiovascular causes compared to aspirin alone in patients with symptomatic atherothrombosis or multiple risk factors?
RCT
Does clopidogrel plus aspirin reduce the rate of myocardial infarction, stroke, or death from cardiovascular causes compared to aspirin alone in patients with symptomatic atherothrombosis or multiple risk factors?
Adding clopidogrel to aspirin does not significantly reduce major cardiovascular events compared to aspirin alone in a broad population with or at risk for atherothrombosis.
Answers are grounded in this paper and cite their sources.
No support for adding clopidogrel to aspirin in symptomatic atherothrombosis or risk factors; challenges routine dual therapy beyond acute settings.
In this trial, there was a suggestion of benefit with clopidogrel treatment in patients with symptomatic atherothrombosis and a suggestion of harm in patients with multiple risk factors. Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke, or death from cardiovascular causes. (ClinicalTrials.gov number, NCT00050817.).
No takes yet. Share an insight, caveat, or question.
Bhatt et al. (2006) conducted an RCT in Atherothrombosis or multiple cardiovascular risk factors. Clopidogrel plus aspirin vs. Aspirin alone was evaluated on Myocardial infarction, stroke, or death from cardiovascular causes. Clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing myocardial infarction, stroke, or cardiovascular death.
Synapse has enriched 10 related papers. Consider them for comparative context: